 |
|
Using the Mayo Imaging Classification to predict renal outcomes in Korean autosomal dominant polycystic kidney disease patients
Yeonsoon Jung
Kidney Res Clin Pract. 2022;41(4):389-392. Published online 2022 Jul 19 DOI: https://doi.org/10.23876/j.krcp.22.016
|
|
Citations to this article as recorded by
 Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
Yaerim Kim, Seungyeup Han
The Korean Journal of Internal Medicine.2023; 38(3): 322. CrossRef Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: A retrospective cohort study using Shizuoka Kokuho Database
Ryuta Saito, Hiroyuki Yamamoto, Nao Ichihara, Hiraku Kumamaru, Shiori Nishimura, Koki Shimada, Kiyoshi Mori, Yoshiki Miyachi, Hiroaki Miyata
Medicine.2022; 101(40): e30923. CrossRef
|